Ignite Creation Date:
2024-05-06 @ 2:34 PM
Last Modification Date:
2024-10-26 @ 1:33 PM
Study NCT ID:
NCT04351334
Status:
COMPLETED
Last Update Posted:
2023-03-27
First Post:
2020-04-15
Brief Title:
Anaplastic Lymphoma Kinase ALK-Positive Non-small Cell Lung Cancer NSCLC Post-alectinib Treatment Patterns
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With Alectinib
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to understand patient profiles treatment patterns and clinical outcomes among ALK-positive NSCLC patients treated with alectinib and post-alectinib treatment patterns and outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None